STAT3-RANTES autocrine signaling is essential for tamoxifen resistance in human breast cancer cells

Molecular Cancer Research

Volumn 11, Issue 1, 2013, Pages 31-42

  Yi, Eun Hee ^a   Lee, Chang Seok ^a   Lee, Jin Ku ^a   Lee, Young Ju ^a   Shin, Min Kyung ^a   Cho, Chung Hyun ^a   Kang, Keon Wook ^a   Lee, Jung Weon ^a   Han, Wonshik ^a   Noh, Dong Young ^a   Kim, Yong Nyun ^c   Cho, Ik Hyun ^b   Ye, Sang Kyu ^a  

^a Seoul National University   (South Korea)

^b Kyung Hee University   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL 2; RANTES; STAT3 PROTEIN; TAMOXIFEN;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER CELL CULTURE; CELL DEATH; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC AGENTS, HORMONAL; AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHEMOKINE CCL5; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; TAMOXIFEN; TRANSFECTION;

EID: 84873033728     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0217     Document Type: Article

References (51)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
3. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, et al. Elevated levels of epidermal growth factor receptor/cerbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144: 1032-44.
4. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-76.
5. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000;355:1822.
6. DeGraffenried LA, Friedrichs WE, Fulcher L, Fernandes G, Silva JM, Peralba JM, et al. Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Ann Oncol 2003;14: 1051-6.
7. Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R, et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 2006;118:290-301.
8. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19: 2468-73.
9. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006;12:20-8.
10. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-8.
11. Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in antiapoptosis. Immunity 1996;5:449-60.
12. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
13. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001;98:762-70.
14. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62:6659-66.
15. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 2003;9:594-600.
16. Nagpal JK, Mishra R, Das BR. Activation of Stat-3 as one of the early events in tobacco chewing - Mediated oral carcinogenesis. Cancer 2002;94:2393-400.
17. Hsiao JR, Jin YT, Tsai ST, Shiau AL, Wu CL, Su WC. Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 2003;89:344-9.
18. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
19. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000;19:2489-95.
20. Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E, Smith PD. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol 2001;19:1155-60.
21. Li L, Shaw PE. Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J Biol Chem 2002;277:17397-405.
22. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anti Cancer Drug 2005;16:601-7.
23. Huang CY, Fong YC, Lee CY, Chen MY, Tsai HC, Hsu HC, et al. CCL5 increases lung cancer migration via PI3K Akt and NF-kappa B pathways. Biochem Pharmacol 2009;77:794-803.
24. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999;59:4681-7.
25. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-9.
26. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poorprognosis gene expression signature. Clin Cancer Res 2004;10:6789- 95.
27. Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, et al. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 2008;44:191-200.
28. Mrowietz U, Schwenk U, Maune S, Bartels J, Kupper M, Fichtner I, et al. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 1999;79:1025-31.
29. Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer 2007;14:293-303.
30. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci 1998;5:79-85.
31. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao YX, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
32. Watson CJ, Miller WR. Elevated levels of members of the Stat family of transcription factors in breast-carcinoma nuclear extracts. Br J Cancer 1995;71:840-4.
33. Hsieh FC, Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 2005;335:292-9.
34. Blanquart C, Karouri SE, Issad T. Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen. Biochem Biophys Res Commun 2009;387:748-53.
35. Page C, Huang M, Jin XH, Cho K, Lilja J, Reynolds RK, et al. Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. Int J Oncol 2000;17:23-8.
36. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997;94:3801-4.
37. DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao SJ, et al. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 2003;22:7781-95.
38. Kim JE, Kim HS, Shin YJ, Lee CS, Won C, Lee SA, et al. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp Mol Med 2008;40:514-22.
39. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63.
40. Kovacic JC, Gupta R, Lee AC, Ma MC, Fang F, Tolbert CN, et al. Stat3- dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice. J Clin Invest 2010;120:303-14.
41. Yang JB, Liao XD, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NF kappa B. Gene Dev 2007; 21:1396-408.
42. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:3803-12.
43. Mi ZY, Bhattacharya SD, Kim VM, Guo HT, Talbot LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011;32:477-87.
44. Kim HJ, Hwang JY, Kim HJ, Choi WS, Lee JH, Kim HJ, et al. Expression of a peroxisomeproliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress. Clin Cancer Res 2007; 13:2577-83.
45. McCarroll JA, Gan PP, Liu M, Kavallaris M. beta III-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 2010;70:4995-5003.
46. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-42.
47. Real PJ, Sierra A, de Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002; 21:7611-8.
48. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006;12:11-9.
49. Pazdrak K, Olszewska-Pazdrak B, Liu T, Takizawa R, Brasier AR, Garofalo RP, et al. MAPK activation is involved in posttranscriptional regulation of RSV-induced RANTES gene expression. Am J Physiol Lung Cell Mol Physiol 2002;283:L364-72.
50. Hashimoto S, Gon Y, Asai Y, Machino T, Jibiki I, Takeshita I, et al. p38 MAP kinase regulates RANTES production by TNF-alpha-stimulated human pulmonary vascular endothelial cells. Allergy 1999;54: 1168-72.
51. Wong M, Uddin S, Majchrzak B, Huynh T, Proudfoot AE, Platanias LC, et al. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 2001;276: 11427-31.